GPCR/G protein


All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B6436 SM-21 maleateSummary: Increases release of acetylcholine,σ2 antagonist -
B6454 Efaroxan hydrochlorideSummary: α2 adrenoceptor antagonist and imidazoline I1 receptor ligand -
B6455 Idazoxan hydrochlorideSummary: α2-adrenoceptor antagonist -
B6464 ICI 89406Summary: β-adrenergic antagonist -
B6475 MPPGSummary: mGlu receptor antagonist -
B6479 MDL 11,939Summary: 5-HT2A receptor antagonist -
B6483 LuzindoleSummary: Melatonin antagonist -
B6484 OleamideSummary: CB1 cannabinoid receptor agonist -
B6485 PalmitoylethanolamideSummary: GPR55 agonist -
B6489 BD 1063 dihydrochloride1 CitationSummary: σ1 receptor antagonist,potent and selective

